Ivor MacLeod
Vermögen: 42 556 $ am 31.05.2026
Vermögen: 42 556 $ am 31.05.2026
Ivor MacLeod is currently Chief Financial Officer at SCYNEXIS, Inc. since 2022.
Formerly, Mr. MacLeod was Chief Financial & Accounting Officer at Athersys, Inc. from 2021 to 2022, Chief Financial & Compliance Officer, SVP at Eisai, Inc. from 2015 to 2018, Vice President-Finance at Merck & Co., Inc. from 2012 to 2015, and Vice President-Finance & Information Technology at Hoffmann-La Roche, Inc. Education includes undergraduate studies at the University of St. Andrews.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
SCYNEXIS, INC. 0,08 % | 01.04.2026 | 60.363 ( 0,08 % ) | 42 556 $ | 31.05.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| SCYNEXIS, INC. | Finanzdirektor/CFO | 24.10.2022 |
| Unternehmen | Position | Ende |
|---|---|---|
| ATHERSYS, INC. | Finanzdirektor/CFO | 30.06.2022 |
Eisai, Inc.
Eisai, Inc. Pharmaceuticals: MajorHealth Technology Manufacturers pharmaceutical products | Finanzdirektor/CFO | 01.01.2018 |
| MERCK & CO., INC. | Finanzdirektor/CFO | 01.01.2015 |
Hoffmann-La Roche, Inc.
Hoffmann-La Roche, Inc. BiotechnologyHealth Technology Operates as a biotech company that develops pharmaceutical and diagnostic solutions | Finanzdirektor/CFO | - |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 7 |
|---|---|
Merck & Co., Inc.
Merck & Co., Inc. Pharmaceuticals: MajorHealth Technology Manufactures human and animal health pharmaceutical products & vaccines | Health Technology |
Hoffmann-La Roche, Inc.
Hoffmann-La Roche, Inc. BiotechnologyHealth Technology Operates as a biotech company that develops pharmaceutical and diagnostic solutions | Health Technology |
Eisai, Inc.
Eisai, Inc. Pharmaceuticals: MajorHealth Technology Manufacturers pharmaceutical products | Health Technology |
SCYNEXIS, Inc.
SCYNEXIS, Inc. Pharmaceuticals: MajorHealth Technology Develops novel oral and intravenous triterpenoid antifungal for the treatment of several serious fungal infections | Health Technology |
University of St. Andrews
University of St. Andrews Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Athersys, Inc.
Athersys, Inc. BiotechnologyHealth Technology Operates as biotechnology company that develops novel and proprietary therapies | Health Technology |
Eller College of Management
Eller College of Management Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen